Literature DB >> 3875604

Evaluation of the in-vitro antibacterial activity of Sch 34343.

C Adam, L Naples, W Weiss, F Sabatelli, R Hare, D Loebenberg, G H Miller.   

Abstract

The in-vitro activity (as measured by geometric mean MICs, mg/l) of Sch 34343 against aerobic and anaerobic bacteria was compared with that of 14 other selected beta-lactam antibiotics including aztreonam, latamoxef (moxalactam), ceftazidime and imipenem. Sch 34343 had good activity (less than 2 mg/l) against most Gram-negative aerobic bacteria whether or not they contained high levels of plasmid-mediated or chromosomally-mediated beta-lactamases. It was slightly less potent against strains of Morganella and Serratia (less than 4 mg/l) and inactive against Pseudomonas (greater than 64 mg/l). A very small inoculum effect was observed against strains containing beta-lactamases indicating stability. Unlike the third-generation cephalosporins, Sch 34343 had excellent activity (less than or equal to 0.18 mg/l) against staphylococci, comparable to that of imipenem and ampicillin. While Sch 34343 had equally good potency (0.17 mg/l) against penicillinase-positive staphylococci, it was inactive against methicillin-resistant staphylococci (greater than or equal to 35 mg/l). Sch 34343 also had good activity against streptococci. The most unusual aspect of the in-vitro activity was its activity against Bacteroides (including Bact. fragilis) and other anaerobes. Sch 34343 had mean MICs less than or equal to mg/l for all Bacteroides and Clostridium spp. tested except CI. difficile (3.4 mg/l).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875604     DOI: 10.1093/jac/15.suppl_c.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  1 in total

1.  Pharmacokinetics and metabolism of an intravenously administered penem (Sch 34343) in humans.

Authors:  C C Lin; J Lim; E Radwanski; H K Kim; A Marco; A Lapiguera; C DiGiore; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.